| News

The innovation campus GRID is filling up


Two institutes from the University of Basel and a pharmaceutical company are relocating to the GRID innovation campus, which is currently under construction at BaseLink in Allschwil. The new building will also contain the headquarters of the Switzerland Innovation Park Basel Area in future.

Visualization of the GRID (img: Herzog & de Meuron)

More tenants have signed lease agreement for office space and laboratories at the GRID (in French: Grand Réseau d’Innovation et de Développement). The GRID, which covers a total area of 50,000 square meters, is considered a key pillar in the emerging biotech cluster of Allschwil and is regarded as one of the most important Life Sciences ecosystems in Switzerland. The new, striking building in a campus style was designed by Herzog & de Meuron architects and developed by SENN Construction AG, which is based in St. Gallen. The Switzerland Innovation Park Basel Area has been a strategic partner and anchor tenant at the GRID since the fall of 2019.

As outlined in a press release issued by SENN, two institutes of the University of Basel are to relocate to the GRID. The Department of Biomedical Engineering (DBE), which is sponsored by both the University of Basel and the University Hospital Basel will move into an area of around 3,500 square meters in 2023 where it will therefore be able to realize its planned growth. Current plans envisage the creation of around 150 jobs, while there will also be space for approximately 100 students. This new facility will also allow the DBE to conduct intensive collaborations with external partners.

According to SENN, the University of Basel will also be represented at the GRID by way of its Innovation Office, the central point of contact for all matters related to innovation and entrepreneurship. From the start of 2021, this department will move into office space at the “Innovation Garage” on the ground floor of the adjacent car park west.

Furthermore the biopharmaceutical company Basilea Pharmaceutica AG will move into the GRID in the middle of 2022 and bring together its teams distributed across other sites. “We will benefit from the close proximity to innovative startup companies, academic institutions and other biotech companies in the emerging life sciences and technology cluster”, comments CEO David Veitch in a press release. In addition, Basilea expects to leverage positive effects on its operating and capital expenses on the back of this move.

“We are delighted to have taken another step closer to achieving our vision of becoming a reference point for anything that can help to improve people’s lives in the future”, explains Johannes Senn, CEO of SENN.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Yokogawa establishes innovation center in Allschwil

The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel gains new biotech in Bright Peak

Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.

Read More
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Robots from Basel set to revolutionize surgery

The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.

Read More
Basel Area Business & Innovation, Innovation

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.

Read More
Basel Area Business & Innovation, Innovation

Versameb raises 6 million Swiss francs

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Read More
Basel Area Business & Innovation, Innovation

Genedata accelerating drug development

Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.

Read More
1 2 3 32

Do you have a question? We'd like to hear from you.